Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Stanton Gerson MD, Case Comprehensive Cancer Center Identifier:
First received: December 31, 2010
Last updated: April 16, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2018
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)